Design Therapeutics/DSGN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Design Therapeutics

Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The Company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.

Ticker

DSGN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Pratik Shah

Employees

57

Headquarters

Carlsbad, United States

DSGN Metrics

BasicAdvanced
$229M
Market cap
-
P/E ratio
-$1.05
EPS
-
Beta
-
Dividend rate
$229M
$8.31
$1.94
296K
38.608
-19.44%
-20.15%
-19.98%
0.849
0.849
15.80%

What the Analysts think about DSGN

Analyst Ratings

Majority rating from 3 analysts.
Hold

DSGN Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$11M
-5.93%
Profit margin
0.00%
NaN%

DSGN Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 24.05%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.36
-$0.28
-$0.21
-$0.20
-
Expected
-$0.40
-$0.41
-$0.31
-$0.26
-$0.23
Surprise
-9.43%
-31.46%
-32.20%
-24.05%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Design Therapeutics stock?

Design Therapeutics (DSGN) has a market cap of $229M as of June 20, 2024.

What is the P/E ratio for Design Therapeutics stock?

The price to earnings (P/E) ratio for Design Therapeutics (DSGN) stock is 0 as of June 20, 2024.

Does Design Therapeutics stock pay dividends?

No, Design Therapeutics (DSGN) stock does not pay dividends to its shareholders as of June 20, 2024.

When is the next Design Therapeutics dividend payment date?

Design Therapeutics (DSGN) stock does not pay dividends to its shareholders.

What is the beta indicator for Design Therapeutics?

Design Therapeutics (DSGN) does not currently have a Beta indicator.

What is the Design Therapeutics stock price target?

The target price for Design Therapeutics (DSGN) stock is $6.67, which is NaN% below the current price of $. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Design Therapeutics stock

Buy or sell Design Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing